Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
167 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Seasonal Influenza - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Seasonal Influenza - Pipeline Review, H1 2015’, provides an overview of the Seasonal Influenza’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Seasonal Influenza Overview 9 Therapeutics Development 10 Pipeline Products for Seasonal Influenza - Overview 10 Pipeline Products for Seasonal Influenza - Comparative Analysis 11 Seasonal Influenza - Therapeutics under Development by Companies 12 Seasonal Influenza - Therapeutics under Investigation by Universities/Institutes 16 Seasonal Influenza - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Seasonal Influenza - Products under Development by Companies 20 Seasonal Influenza - Products under Investigation by Universities/Institutes 24 Seasonal Influenza - Companies Involved in Therapeutics Development 25 AIMM Therapeutics B.V. 25 AltraVax Inc. 26 AmVac AG 27 Baxter International Inc. 28 Big DNA Ltd. 29 BioDiem Ltd 30 Celltrion, Inc. 31 Cilian AG 32 Codagenix, Inc. 33 ContraFect Corporation 34 Crucell N.V. 35 Eurocine Vaccines AB 36 FluGen, Inc. 37 GlaxoSmithKline plc 38 Hemispherx Biopharma, Inc. 39 Inovio Pharmaceuticals, Inc. 40 Johnson & Johnson 41 Liquidia Technologies, Inc. 42 Medicago Inc. 43 Merck & Co., Inc. 44 Novartis AG 45 Novavax, Inc. 46 OPKO Health, Inc. 47 PeptiVir, Inc. 48 Protein Sciences Corporation 49 TechnoVax, Inc. 50 Theraclone Sciences, Inc. 51 Touchlight Genetics Ltd. 52 TSRL, Inc. 53 Vaxart, Inc. 54 Vaxine Pty Ltd 55 VaxInnate Corporation 56 Vivaldi Biosciences Inc. 57 Zydus Cadila Healthcare Limited 58 Seasonal Influenza - Therapeutics Assessment 59 Assessment by Monotherapy Products 59 Assessment by Combination Products 60 Assessment by Target 61 Assessment by Mechanism of Action 63 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (influenza B virus + influenza A virus [H3N2] + influenza A virus [H1N1]) vaccine - Drug Profile 69 A-06 - Drug Profile 70 Alferon LDO - Drug Profile 71 AMV-401 - Drug Profile 72 BDNA-002 - Drug Profile 73 Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza - Drug Profile 74 CF-404 - Drug Profile 75 CiFlu - Drug Profile 76 CR-8020 - Drug Profile 78 CTP-25 - Drug Profile 80 CTP-27 - Drug Profile 81 FluCell - Drug Profile 82 FVH-1 - Drug Profile 83 IKT-041 - Drug Profile 84 Influ-nRNA - Drug Profile 85 influenza (quadrivalent) vaccine - Drug Profile 86 influenza (split virion, trivalent) vaccine - Drug Profile 88 influenza (trivalent) vaccine - Drug Profile 89 influenza (trivalent) vaccine - Drug Profile 90 influenza (trivalent) vaccine - Drug Profile 91 influenza [A/Christchurch/16/2010 (H1N1) + A/Texas/50/2012 (H3N2) + B/Massachusetts/02/2012 + B/Brisbane/60/2008] (split virion) vaccine - Drug Profile 92 influenza [H1N1] (quadrivalent) virus like particle vaccine - Drug Profile 94 influenza [strain A/H1N1] + [strain A/H3N2] + [strain B] (split virion) vaccine - Drug Profile 96 influenza [strain H1N1] (monovalent) vaccine - Drug Profile 98 influenza vaccine - Drug Profile 100 influenza vaccine - Drug Profile 101 influenza vaccine - Drug Profile 102 influenza vaccine - Drug Profile 104 INO-3510 - Drug Profile 105 LIQ-001 - Drug Profile 106 Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 107 NB-1008 - Drug Profile 108 PVI-1000 - Drug Profile 109 respiratory syncytical virus + influenza vaccine - Drug Profile 110 seasonal influenza (quadrivalent) vaccine - Drug Profile 111 seasonal influenza (trivalent) vaccine - Drug Profile 112 seasonal influenza (trivalent) vaccine - Drug Profile 115 seasonal influenza [A/H1N1, A/H3N2, B/Yamagata, B/Victoria] (quadrivalent) vaccine - Drug Profile 116 seasonal influenza [B/Yamagata] (monovalent) vaccine - Drug Profile 117 seasonal influenza [H3N2] vaccine - Drug Profile 118 seasonal influenza B vaccine - Drug Profile 119 seasonal influenza vaccine - Drug Profile 120 seasonal influenza vaccine - Drug Profile 121 seasonal influenza vaccine - Drug Profile 122 seasonal influenza vaccine - Drug Profile 123 Small Molecules for Influenza - Drug Profile 124 Small Molecules to Activate Sirtuin for Influenza - Drug Profile 125 TAK-850 - Drug Profile 126 TCN-032 - Drug Profile 127 TSR-026 - Drug Profile 129 TSR-462 - Drug Profile 130 TVX-001 - Drug Profile 131 VAX-2012Q - Drug Profile 132 VB126 LAIV - Drug Profile 133 VH-244 - Drug Profile 134 VX-787 - Drug Profile 136 VXAA-1.1 - Drug Profile 137 Seasonal Influenza - Recent Pipeline Updates 138 Seasonal Influenza - Dormant Projects 153 Seasonal Influenza - Discontinued Products 155 Seasonal Influenza - Product Development Milestones 156 Featured News & Press Releases 156 Appendix 162 Methodology 162 Coverage 162 Secondary Research 162 Primary Research 162 Expert Panel Validation 162 Contact Us 162 Disclaimer 163
List of Tables Number of Products under Development for Seasonal Influenza, H1 2015 14 Number of Products under Development for Seasonal Influenza - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2015 20 Comparative Analysis by Late Stage Development, H1 2015 21 Comparative Analysis by Clinical Stage Development, H1 2015 22 Comparative Analysis by Early Stage Development, H1 2015 23 Products under Development by Companies, H1 2015 24 Products under Development by Companies, H1 2015 (Contd..1) 25 Products under Development by Companies, H1 2015 (Contd..2) 26 Products under Development by Companies, H1 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2015 28 Seasonal Influenza - Pipeline by AIMM Therapeutics B.V., H1 2015 29 Seasonal Influenza - Pipeline by AltraVax Inc., H1 2015 30 Seasonal Influenza - Pipeline by AmVac AG, H1 2015 31 Seasonal Influenza - Pipeline by Baxter International Inc., H1 2015 32 Seasonal Influenza - Pipeline by Big DNA Ltd., H1 2015 33 Seasonal Influenza - Pipeline by BioDiem Ltd, H1 2015 34 Seasonal Influenza - Pipeline by Celltrion, Inc., H1 2015 35 Seasonal Influenza - Pipeline by Cilian AG, H1 2015 36 Seasonal Influenza - Pipeline by Codagenix, Inc., H1 2015 37 Seasonal Influenza - Pipeline by ContraFect Corporation, H1 2015 38 Seasonal Influenza - Pipeline by Crucell N.V., H1 2015 39 Seasonal Influenza - Pipeline by Eurocine Vaccines AB, H1 2015 40 Seasonal Influenza - Pipeline by FluGen, Inc., H1 2015 41 Seasonal Influenza - Pipeline by GlaxoSmithKline plc, H1 2015 42 Seasonal Influenza - Pipeline by Hemispherx Biopharma, Inc., H1 2015 43 Seasonal Influenza - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 44 Seasonal Influenza - Pipeline by Johnson & Johnson, H1 2015 45 Seasonal Influenza - Pipeline by Liquidia Technologies, Inc., H1 2015 46 Seasonal Influenza - Pipeline by Medicago Inc., H1 2015 47 Seasonal Influenza - Pipeline by Merck & Co., Inc., H1 2015 48 Seasonal Influenza - Pipeline by Novartis AG, H1 2015 49 Seasonal Influenza - Pipeline by Novavax, Inc., H1 2015 50 Seasonal Influenza - Pipeline by OPKO Health, Inc., H1 2015 51 Seasonal Influenza - Pipeline by PeptiVir, Inc., H1 2015 52 Seasonal Influenza - Pipeline by Protein Sciences Corporation, H1 2015 53 Seasonal Influenza - Pipeline by TechnoVax, Inc., H1 2015 54 Seasonal Influenza - Pipeline by Theraclone Sciences, Inc., H1 2015 55 Seasonal Influenza - Pipeline by Touchlight Genetics Ltd., H1 2015 56 Seasonal Influenza - Pipeline by TSRL, Inc., H1 2015 57 Seasonal Influenza - Pipeline by Vaxart, Inc., H1 2015 58 Seasonal Influenza - Pipeline by Vaxine Pty Ltd, H1 2015 59 Seasonal Influenza - Pipeline by VaxInnate Corporation, H1 2015 60 Seasonal Influenza - Pipeline by Vivaldi Biosciences Inc., H1 2015 61 Seasonal Influenza - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 62 Assessment by Monotherapy Products, H1 2015 63 Assessment by Combination Products, H1 2015 64 Number of Products by Stage and Target, H1 2015 66 Number of Products by Stage and Mechanism of Action, H1 2015 68 Number of Products by Stage and Route of Administration, H1 2015 70 Number of Products by Stage and Molecule Type, H1 2015 72 Seasonal Influenza Therapeutics - Recent Pipeline Updates, H1 2015 142 Seasonal Influenza - Dormant Projects, H1 2015 157 Seasonal Influenza - Dormant Projects (Contd..1), H1 2015 158 Seasonal Influenza - Discontinued Products, H1 2015 159
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
